Shots:

• The P-III (ECHELON-3) trial assesses Adcetris + lenalidomide and rituximab vs PBO + lenalidomide and rituximab in r/r DLBCL patients (n=230), irrespective of CD30 expression, previously treated with 2 or more lines of therapy and are not eligible for stem cell transplant or CAR-T therapy
• The study demonstrated a 37% reduction in death risk, mOS of 13.8mos. vs 8.5mos., mPFS of 4.2mos. vs 2.6mos., ORR of 64.3% vs 41.5% and CR rate of 40.2% vs 18.6%
• The safety results showed grade 3 or higher TEAEs of neutropenia (43% vs 28%), thrombocytopenia (25% vs 19%) and anemia (22% vs 21%) with low-grade & infrequent peripheral sensory neuropathy and 4% vs 0% grade 3 events

Ref: Pfizer | Image: Pfizer

Related News:- Pfizer Reports P-III Study Results of Adcetris for Treating Diffuse Large B-cell Lymphoma (DLBCL)

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com